Chest Wall Disorder, Chronic Obstructive Pulmonary Disease, Neuromuscular Disease, Obesity Hypoventilation Syndrome, Respiratory Failure
Conditions
Keywords
Non-Invasive Positive-Pressure Ventilation, Disease Exacerbation, Respiratory Failure
Brief summary
The aim of this study is to determine whether respiratory disease exacerbations (a sudden worsening of symptoms) can be predicted by variables that are monitored by non-invasive ventilators (small machines that assist breathing) in patients requiring long term home ventilation. The investigators hypothesise that acute exacerbations of patients with respiratory disease and ventilatory failure will be predicted by changes in the respiratory variables monitored and stored by ventilators during chronic home ventilator use.
Detailed description
This pilot study is a proof of concept study investigating whether respiratory variables measured during chronic non-invasive ventilation (NIV) therapy may be used to predict a disease exacerbation. Modern ventilators used in the home for chronic respiratory failure have the ability to monitor and store respiratory variables that may worsen during exacerbations, and may potentially detect exacerbations before symptoms become apparent. Normal pressure support ventilators monitor respiratory rate which might be expected to increase with worsening disease. In patients with obstructive airways disease an increase in expiratory time may potentially be observed with worsening airways obstruction. Adaptive servo ventilators, which modulate pressure support to maintain constant minute ventilation, may increase the amount of pressure support delivered if respiratory mechanics deteriorate as a result of an exacerbation. Consenting experienced NIV users will be switched to an adaptive-servo ventilator with the capacity to monitor and store therapy data. The device being used is the Stellar 150 ventilator (Resmed, Ltd., Bella Vista, Australia) with hardware and software ability to measure variables such as respiratory rate, airflow, pressure support and leak. Patients will use the ventilator for a total of 4 months during which they will complete daily symptom diaries, including medication use and peak flow measurements. Changes in ventilator variables will be analysed and day to day variation identified. Changes will be compared with daily peak expiratory flow measures (an indication of how well the airways are functioning), patient symptoms, and healthcare utilization. Hospital admissions for exacerbations, GP consults, and healthcare team contacts will also be measured.
Interventions
DEVICEiVAPS ventilation
3 months of ventilation on iVAPS mode
Sponsors
ResMed
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of obstructive (COPD, cystic fibrosis, bronchiectasis or chronic asthma) or restrictive (NMD, chest wall disorder) lung disease confirmed by a hospital consultant * aged \> 18 years * established home ventilator user with ventilator prescribed for either chronic ventilatory failure or nocturnal hypoventilation * able to use bilevel positive pressure ventilation with Inspiratory positive airway pressure (IPAP) requirement \<30cm H2O (Stellar ventilator - IPAP max 30)
Exclusion criteria
* patients \< 18 years * cognitive impairment sufficient to interfere with comprehension of the study or use of ventilator * poor adherence with non-invasive ventilation (\<3hours/night for \>10days/month) * Inspiratory positive airway pressure (IPAP) requirement \>30cmH2O
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ventilator pressure support from baseline | up to 3 months | Pressure Support delivered by the adaptive-servo ventilator at Day 0 of exacerbation compared to the pressure support during baseline stable state. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in ventilator-measured parameters from baseline | Up to 3 months | Changes in ventilator-measured parameters \>15% from baseline \[respiratory rate (RR), inspiratory time (Ti), pressure support (PS), Minute volume (MV), tidal volume (Vt), flow, leak, oxygen saturation (SaO2), pulse, I:E ratio, apnoea-hypopnea index (AHI), compliance\] |
| Exacerbation as determined by a change in patients subjective symptoms | up to 3 months | The presence of 2 or more subjective symptoms compared to baseline for 2 consecutive days; \- breathlessness, increased sputum volume or sputum purulence, coryzal, wheeze or chest tightness, sore throat, cough, fever, sleep disruption, decreased physical activity |
| Change in peak expiratory flow rate (PEFR)>15% from baseline | Up to 3 months | Change in peak expiratory flow rate (PEFR)\>15% from baseline |
| Exacerbation as defined by healthcare utilisation | up to 3 months | Exacerbation defined by the requirement of antibiotics +/- steroids, GP visit, accident and emergency visit, hospital admission |
Countries
United Kingdom
Outcome results
None listed